Key facts
- It has raised $52.1M; the latest was Later Stage VC in Mar 2025.
- Notable investors include Fortune Capital, Shenzhen Guozhong Venture Capital Management, Lapam Capital, Beijing Delian Yuntong Investment Management Company, Bosera Capital — 11 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 11 names
- ·Watchlist + deal alerts for Chance Pharmaceuticals
- ·The full record, as it builds
Funding rounds
No funding rounds for Chance Pharmaceuticals are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Chance Pharmaceuticals
Developer of generic drugs created to cure chronic obstructive pulmonary disease. The company's drugs are provided in dry powder inhalation delivery systems, enabling researchers to reduce costs by transforming manufacturing technology of powder aerosols.
- Sector
- Healthcare
- HQ
- Hangzhou, China
- Founded
- 2015
- Website
- chancepharmaceuticals.com/
- Ownership
- Privately Held (backing)
Chance Pharmaceuticals doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Chance Pharmaceuticals shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Chance Pharmaceuticals in its N-PORT filings yet. We sweep new filings monthly.